These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11344382)

  • 1. Rifampicin pharmacokinetics with and without ciprofloxacin.
    Orisakwe OE; Agbasi PU; Afonne OJ; Ofoefule SI; Obi E; Orish CN
    Am J Ther; 2001; 8(3):151-3. PubMed ID: 11344382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin.
    Orisakwe OE; Akunyili DN; Agbasi PU; Ezejiofor NA
    Am J Ther; 2004; 11(4):283-7. PubMed ID: 15266220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion of rifampicin in the presence of ciprofloxacin.
    Orisakwe OE; Afonne OJ; Agbasi PU; Ofoefule SI
    Am J Ther; 2004; 11(3):171-4. PubMed ID: 15133531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pefloxacin on the urinary excretion of rifampicin.
    Orisakwe OE; Agbasi PU; Ofoefule SI; Ilondu NA; Afonne OJ; Anusiem CA; Ilo CE; Maduka SO
    Am J Ther; 2004; 11(1):13-6. PubMed ID: 14704591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis.
    Le Doare K; Barber N; Doerholt K; Sharland M
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23355589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
    Kelkar MS; Saraf AP; Bakhle DS; Nazare V; Ajay S; Hegde S; Lal HM; Cooverji ND; Bruzzese T
    Int J Clin Pharmacol Res; 1998; 18(3):137-43. PubMed ID: 9825270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.
    Conte JE; Golden JA; Kipps JE; Lin ET; Zurlinden E
    Clin Pharmacokinet; 2004; 43(6):395-404. PubMed ID: 15086276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.
    Svensson RJ; Aarnoutse RE; Diacon AH; Dawson R; Gillespie SH; Boeree MJ; Simonsson USH
    Clin Pharmacol Ther; 2018 Apr; 103(4):674-683. PubMed ID: 28653479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Food on Rifampicin Pharmacokinetics in Rats.
    Shimomura H; Nogami R; Shigeno A; Shimada S; Aoyama T
    Biol Pharm Bull; 2016; 39(1):49-53. PubMed ID: 26725427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma pooling methodology as a faster and cheaper tool to evaluate bioequivalence of rifampicin component of FDCs of antitubercular drugs.
    Panchagnula R; Sharma A; Agrawal S
    Pharmacol Res; 2003 Dec; 48(6):655-63. PubMed ID: 14527833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.
    Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S
    J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients.
    Jaruratanasirikul S; Sriwiriyajan S
    J Pharm Pharmacol; 2001 Mar; 53(3):409-12. PubMed ID: 11291758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur JK; Singh I; Bhade SR
    Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):161-7. PubMed ID: 16810342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients.
    Jaruratanasirikul S; Kleepkaew A
    J Antimicrob Chemother; 1996 Nov; 38(5):877-80. PubMed ID: 8961059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):697-9. PubMed ID: 15971401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between ciprofloxacin and rifampin.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999; 33(7-8):868-70. PubMed ID: 10466918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.